Summary: Background and objective. Tumor heterogeneity is shown to be related to clinical outcome in cancer patients. The concept of a small subset of cancer stem cells being responsible for tumor relapse and metastasis comes out as a promising strategy for targeted cancer therapy. However, cancer stem cells are not easy to identify and isolate. The aim of this study was to determine the putative colon cancer stem cell subsets in human colon cancer cell lines HCT116 and HT29, which differ in their aggressiveness and differentiation capacity.
(2013). Cervical Cancer. Retrieved from http://www21.ha.org.hk/ smartpatient/en/cancerin_focus/details.html?id=152 Lie, A. K., & Kristensen, G. (2008). Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert review of molecular diagnostics, 8(4), 405-415.
Implications of Cancer Stem Cell Theory for Cancer Chemoprevention by Natural Dietary Compounds. Retrieved December 12, 2013, from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248810/ Nikitina, E. G., Urazova, L. N., & Stegny, V. N. (2012). MicroRNAs and Human Cancer.Experimental Oncology, 34(1), 2-8. Retrieved from http://archive.nbuv.gov.ua/portal/chem_biol/eol/2012_1/002.pdf Wang, K., Wu, X., & Huang, J. (2013, February 28).
This plan will not only help current and future patients conquer cancer, it will provide valuable information about the disease and doctors and scientists can... ... middle of paper ... ... 207-214. Patyar, S., Joshi, R., Prasad, D., Prakash, A., Medhi, B., and Das, B. (2010). Bacteria in cancer therapy: a novel experimental strategy. Journal of Biomedical Science, 17. doi:10.1186/1423-0127-17-21 Prica, A., Chan, K., & Cheung, M. (2012).
2013 January ; 13(1): 66–74. doi:10.1038/nrc3420. 4. Klein Alison P. Genetic Susceptibility to Pancreatic Cancer. Mol Carcinog.
Davis, David A., Sarah H. Sarkar, Maha Hussain, Yiwei Li, and Fazlul H. Sarkar. "Increased Therapeutic Potential of an Experimental Anti-mitotic Inhibitor SB715992 by Genistein in PC-3 Human Prostate Cancer Cell Line." BMC Cancer 6.22 (2006): 1-9. 22. Chen, Dongfeng, Xubo Wu, Jiaxiang Wang, Baosan Han, Ping Zhu, and Chenghong Peng.
William ... ... middle of paper ... ...atments by using immunotherapy as a treatment. Works Cited Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clinical cancer research: an official journal of the American Association for Cancer Research. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention.
These oncogenes cause cancer because they do not allow the cells to self destruct or become epistatic. There have been several research projects which have been testing epistatis. Transfecting DNA To perform the experiments for this re... ... middle of paper ... ...wth of both normal and malignant cells. The limited research that has been performed using these cells has yielded contradictory results: some results say that the alpha5beta1 integrins destroy cancer cells, other results have shown that cell division and other necessary cell functions have been encouraged by the integrin. But the research has predominantly shown that the results of the expression of alpha5beta1 integrins yield beneficial results in terms of cancer tumor reduction.
sensor, 10, 428-455. Brigger I, Duberne C, Couvreur P, (2002). Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 54, 631-651. Jain P, El-sayed I, El-sayed M ,( 2007) .
8. Pópulo H, Lopes JM, Soares P. (2012). The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci. 13 (2), 1886-918.